Leading Expertise. Limitless Ambition.

Leading Expertise. Limitless Ambition.

  • All
  • Founders
  • Management
  • All
  • Founders
  • Management

Shankar Ramaswamy, MD

Co-Founder and CEO

Shankar Ramaswamy, MD

Co-Founder, Chief Executive Officer, and Chairman

Shankar Ramaswamy is the Co-Founder, Chairman, and Chief Executive Officer of Kriya Therapeutics. Previously, Dr. Ramaswamy was part of the early foundational team at Roivant Sciences, where he was responsible for identifying and evaluating assets across multiple therapeutic areas and launching its first public subsidiary company. He went on to be the Chief Business Officer of Axovant Gene Therapies (now Sio Gene Therapies).

Dr. Ramaswamy received his Medical Degree from Brown University and his undergraduate degree in Economics from Harvard University.

Next   >

Roger Jeffs, PhD

Co-Founder and
Vice Chair

Roger Jeffs, PhD

Co-Founder and Vice Chairman

Roger Jeffs is the Co-Founder and Vice Chairman of Kriya Therapeutics. Previously, Dr. Jeffs was the President and co-CEO of United Therapeutics Corporation, joining the company during its start-up phase in 1998. He helped lead the company’s IPO, oversaw the clinical development and regulatory approval of six products, and managed the commercial efforts that led to a $1.5B annual revenue run rate. He currently serves on the boards of Axsome Therapeutics, Albireo Pharma, and Liquidia Corporation, and previously served on the boards of United Therapeutics, Sangamo Therapeutics, and Dova Pharmaceuticals.

Dr. Jeffs received his PhD in Pharmacology from the University of North Carolina School of Medicine and his undergraduate degree in Chemistry from Duke University.

<   PreviousNext   >

Fraser Wright, PhD

Co-Founder and Chief Scientific Advisor

Fraser Wright, PhD

Scientific Co-Founder and Chief Scientific Advisor

Fraser Wright is the Scientific Co-Founder and Chief Scientific Advisor of Kriya Therapeutics. Dr. Wright is a Professor of Pediatrics in the Center for Definitive and Curative Medicine at Stanford University. Previously, he was the co-founder and Chief Technology Officer of Spark Therapeutics, where he helped oversee the product development and manufacturing of LUXTURNA® and other pipeline programs. Prior to co-founding Spark Therapeutics, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at the Children’s Hospital of Philadelphia. He was also previously the director of development and clinical manufacturing at Avigen.

Dr. Wright received his PhD in Biochemistry and Molecular Immunology and his undergraduate degree in Biochemistry and Physiology from the University of Toronto.

<   Previous

Shankar Ramaswamy, MD

Co-Founder and CEO

Shankar Ramaswamy, MD

Co-Founder, Chief Executive Officer, and Chairman

Shankar Ramaswamy is the Co-Founder, Chairman, and Chief Executive Officer of Kriya Therapeutics. Previously, Dr. Ramaswamy was part of the early foundational team at Roivant Sciences, where he was responsible for identifying and evaluating assets across multiple therapeutic areas and launching its first public subsidiary company. He went on to be the Chief Business Officer of Axovant Gene Therapies (now Sio Gene Therapies).

Dr. Ramaswamy received his Medical Degree from Brown University and his undergraduate degree in Economics from Harvard University.

Next   >

Melissa Rhodes, PhD

Chief Development
Officer

Melissa Rhodes, PhD, DABT

Chief Development Officer

Melissa Rhodes is the Chief Development Officer of Kriya Therapeutics. Previously, Dr. Rhodes was the Chief Development Officer of Aerami Therapeutics, a company focused on inhaled biologic therapies. Prior to Aerami, Dr. Rhodes was the Chief Development Officer of Altavant Sciences, a respiratory rare disease company. Dr. Rhodes also served as Senior Vice President at Roivant Sciences, where she built and led a team of scientists conducting nonclinical research for multiple Roivant subsidiary companies. She spent nearly ten years in R&D at GlaxoSmithKline, and started her career in drug development at an oncology-focused university spin-out company.

Dr. Rhodes received her PhD in Pharmacology and Toxicology from Duke University Medical Center and is a Diplomate of the American Board of Toxicology. Dr. Rhodes completed her postdoctoral fellowship at the National Toxicology Program at the National Institute of Environmental Health Sciences. She received her undergraduate degree in Zoology from North Carolina State University.

<   PreviousNext   >

Britt Petty

Chief Manufacturing
Officer

Britt Petty

Chief Manufacturing Officer

Britt Petty is the Chief Manufacturing Officer of Kriya Therapeutics. Previously, Mr. Petty was the Chief Technical Officer (interim) and Head of Global Manufacturing at AveXis, a Novartis company, focused on the development and commercialization of gene therapies for neurological genetic diseases. At AveXis, he was responsible for manufacturing the company’s commercial and clinical gene therapy products at both internal and external sites across the United States and Europe. Mr. Petty oversaw all supply chain, engineering, program management, and manufacturing science and technology functions. Prior to AveXis, Mr. Petty held senior manufacturing roles at Biogen, including as the site head for the company’s North Carolina facility. He previously held manufacturing roles of increasing responsibility at Amgen and Eli Lily and Co.

Mr. Petty received his MBA from the University of North Carolina at Chapel Hill and his undergraduate degree in Mechanical Engineering from the Rose-Hulman Institute of Technology.

<   PreviousNext   >

Nachi Gupta, MD, PhD

Chief Technology Innovation
Officer

Nachi Gupta, MD, PhD

Chief Technology Innovation Officer

Nachi Gupta is the Chief Technology Innovation Officer of Kriya Therapeutics. Dr. Gupta is a board-certified emergency medicine physician. Prior to his career as a clinician, Dr. Gupta was a quantitative analyst at Brevan Howard Asset Management, a global macro hedge fund. Dr. Gupta was also previously an associate staff member at MIT Lincoln Laboratories, serving on the ballistic missile defense team.

Dr. Gupta received his Medical Degree from Brown University and completed his residency at Mount Sinai Hospital. He received his PhD in Mathematics from Oxford University, and master’s degrees in Computer Science and Mathematics from the University of Pennsylvania. He received his undergraduate degrees in Economics and Engineering from the University of Pennsylvania.

<   PreviousNext   >

Image of David Shin

David Shin, MD

Chief Strategy
Officer

Image of David Shin

David Shin, MD

Chief Strategy Officer

David Shin is the Chief Strategy Officer of Kriya Therapeutics. Previously, Dr. Shin was the Chief Operating Officer of Limelight Bio, a gene therapy company developing multiple technology platforms to address the limitations of viral vectors. Before Limelight, he helped start Alpine Biosciences to develop a nanotechnology platform for large molecule delivery, which was sold to Oncothyreon, a publicly traded oncology company. Prior to Alpine, Dr. Shin was a founding investment professional at Ayer Capital, a healthcare-specific hedge fund, where he managed investments in all subsectors of healthcare. He began his business career as a technology leader in multiple scientific software and device companies serving the biopharmaceutical industry, one of which was sold to Thermo Fisher Scientific where he remained as Director of Technology.

Dr. Shin received his Medical Degree from the University of Pennsylvania School of Medicine and his undergraduate degree in Electrical Engineering from Carnegie Mellon University.

<   PreviousNext   >

Daniel Chen

Chief Financial
Officer

Daniel Chen

Chief Financial Officer

Daniel Chen is the Chief Financial Officer of Kriya Therapeutics. Previously, Mr. Chen worked at Portola Pharmaceuticals for more than 10 years, most recently as Vice President of Business Planning and Corporate Strategy. In that role, he was responsible for leading the financial planning and analysis, treasure, purchasing, and strategic planning functions for the company. Prior to Portola, Mr. Chen held various roles in finance and commercial operations at Johnson & Johnson and Gilead Sciences.

Mr. Chen received his MBA from the University of Southern California and his undergraduate degree in Molecular Cell Biology from the University of California, Berkeley.

<   PreviousNext   >

Dana Johnson

General
Counsel

Dana Johnson

General Counsel

Dana Johnson is the General Counsel of Kriya Therapeutics. Previously, Ms. Johnson was General Counsel at Rakuten Medical, and Vice President and Head of Legal Affairs and Corporate Compliance at Gritstone Oncology. Ms. Johnson has also held roles at BioMarin Pharmaceutical as well as at Reed Smith LLP, a leading global law firm. Ms. Johnson brings extensive legal life sciences industry experience in both private and public companies, in areas as varied as IPOs, complex transactions, corporate governance, litigation, compliance, and ethics.

Ms. Johnson received her JD from the University of San Francisco School of Law and her undergraduate degree in English Literature from Vanderbilt University.

<   Previous

Shankar Ramaswamy, MD

Co-Founder and CEO

Shankar Ramaswamy, MD

Co-Founder, Chief Executive Officer, and Chairman

Shankar Ramaswamy is the Co-Founder, Chairman, and Chief Executive Officer of Kriya Therapeutics. Previously, Dr. Ramaswamy was part of the early foundational team at Roivant Sciences, where he was responsible for identifying and evaluating assets across multiple therapeutic areas and launching its first public subsidiary company. He went on to be the Chief Business Officer of Axovant Gene Therapies (now Sio Gene Therapies).

Dr. Ramaswamy received his Medical Degree from Brown University and his undergraduate degree in Economics from Harvard University.

Next   >

Roger Jeffs, PhD

Co-Founder and
Vice Chair

Roger Jeffs, PhD

Co-Founder and Vice Chairman

Roger Jeffs is the Co-Founder and Vice Chairman of Kriya Therapeutics. Previously, Dr. Jeffs was the President and co-CEO of United Therapeutics Corporation, joining the company during its start-up phase in 1998. He helped lead the company’s IPO, oversaw the clinical development and regulatory approval of six products, and managed the commercial efforts that led to a $1.5B annual revenue run rate. He currently serves on the boards of Axsome Therapeutics, Albireo Pharma, and Liquidia Corporation, and previously served on the boards of United Therapeutics, Sangamo Therapeutics, and Dova Pharmaceuticals.

Dr. Jeffs received his PhD in Pharmacology from the University of North Carolina School of Medicine and his undergraduate degree in Chemistry from Duke University.

<   PreviousNext   >

Fraser Wright, PhD

Co-Founder and Chief Scientific Advisor

Fraser Wright, PhD

Scientific Co-Founder and Chief Scientific Advisor

Fraser Wright is the Scientific Co-Founder and Chief Scientific Advisor of Kriya Therapeutics. Dr. Wright is a Professor of Pediatrics in the Center for Definitive and Curative Medicine at Stanford University. Previously, he was the co-founder and Chief Technology Officer of Spark Therapeutics, where he helped oversee the product development and manufacturing of LUXTURNA® and other pipeline programs. Prior to co-founding Spark Therapeutics, Dr. Wright was the founding Scientific Director of the Clinical Vector Core Laboratory at the Children’s Hospital of Philadelphia. He was also previously the director of development and clinical manufacturing at Avigen.

Dr. Wright received his PhD in Biochemistry and Molecular Immunology and his undergraduate degree in Biochemistry and Physiology from the University of Toronto.

<   PreviousNext   >

Melissa Rhodes, PhD

Chief Development
Officer

Melissa Rhodes, PhD, DABT

Chief Development Officer

Melissa Rhodes is the Chief Development Officer of Kriya Therapeutics. Previously, Dr. Rhodes was the Chief Development Officer of Aerami Therapeutics, a company focused on inhaled biologic therapies. Prior to Aerami, Dr. Rhodes was the Chief Development Officer of Altavant Sciences, a respiratory rare disease company. Dr. Rhodes also served as Senior Vice President at Roivant Sciences, where she built and led a team of scientists conducting nonclinical research for multiple Roivant subsidiary companies. She spent nearly ten years in R&D at GlaxoSmithKline, and started her career in drug development at an oncology-focused university spin-out company.

Dr. Rhodes received her PhD in Pharmacology and Toxicology from Duke University Medical Center and is a Diplomate of the American Board of Toxicology. Dr. Rhodes completed her postdoctoral fellowship at the National Toxicology Program at the National Institute of Environmental Health Sciences. She received her undergraduate degree in Zoology from North Carolina State University.

<   PreviousNext   >

Britt Petty

Chief Manufacturing
Officer

Britt Petty

Chief Manufacturing Officer

Britt Petty is the Chief Manufacturing Officer of Kriya Therapeutics. Previously, Mr. Petty was the Chief Technical Officer (interim) and Head of Global Manufacturing at AveXis, a Novartis company, focused on the development and commercialization of gene therapies for neurological genetic diseases. At AveXis, he was responsible for manufacturing the company’s commercial and clinical gene therapy products at both internal and external sites across the United States and Europe. Mr. Petty oversaw all supply chain, engineering, program management, and manufacturing science and technology functions. Prior to AveXis, Mr. Petty held senior manufacturing roles at Biogen, including as the site head for the company’s North Carolina facility. He previously held manufacturing roles of increasing responsibility at Amgen and Eli Lily and Co.

Mr. Petty received his MBA from the University of North Carolina at Chapel Hill and his undergraduate degree in Mechanical Engineering from the Rose-Hulman Institute of Technology.

<   PreviousNext   >

Nachi Gupta, MD, PhD

Chief Technology Innovation
Officer

Nachi Gupta, MD, PhD

Chief Technology Innovation Officer

Nachi Gupta is the Chief Technology Innovation Officer of Kriya Therapeutics. Dr. Gupta is a board-certified emergency medicine physician. Prior to his career as a clinician, Dr. Gupta was a quantitative analyst at Brevan Howard Asset Management, a global macro hedge fund. Dr. Gupta was also previously an associate staff member at MIT Lincoln Laboratories, serving on the ballistic missile defense team.

Dr. Gupta received his Medical Degree from Brown University and completed his residency at Mount Sinai Hospital. He received his PhD in Mathematics from Oxford University, and master’s degrees in Computer Science and Mathematics from the University of Pennsylvania. He received his undergraduate degrees in Economics and Engineering from the University of Pennsylvania.

<   PreviousNext   >

Image of David Shin

David Shin, MD

Chief Strategy
Officer

Image of David Shin

David Shin, MD

Chief Strategy Officer

David Shin is the Chief Strategy Officer of Kriya Therapeutics. Previously, Dr. Shin was the Chief Operating Officer of Limelight Bio, a gene therapy company developing multiple technology platforms to address the limitations of viral vectors. Before Limelight, he helped start Alpine Biosciences to develop a nanotechnology platform for large molecule delivery, which was sold to Oncothyreon, a publicly traded oncology company. Prior to Alpine, Dr. Shin was a founding investment professional at Ayer Capital, a healthcare-specific hedge fund, where he managed investments in all subsectors of healthcare. He began his business career as a technology leader in multiple scientific software and device companies serving the biopharmaceutical industry, one of which was sold to Thermo Fisher Scientific where he remained as Director of Technology.

Dr. Shin received his Medical Degree from the University of Pennsylvania School of Medicine and his undergraduate degree in Electrical Engineering from Carnegie Mellon University.

<   PreviousNext   >

Daniel Chen

Chief Financial
Officer

Daniel Chen

Chief Financial Officer

Daniel Chen is the Chief Financial Officer of Kriya Therapeutics. Previously, Mr. Chen worked at Portola Pharmaceuticals for more than 10 years, most recently as Vice President of Business Planning and Corporate Strategy. In that role, he was responsible for leading the financial planning and analysis, treasure, purchasing, and strategic planning functions for the company. Prior to Portola, Mr. Chen held various roles in finance and commercial operations at Johnson & Johnson and Gilead Sciences.

Mr. Chen received his MBA from the University of Southern California and his undergraduate degree in Molecular Cell Biology from the University of California, Berkeley.

<   PreviousNext   >

Dana Johnson

General
Counsel

Dana Johnson

General Counsel

Dana Johnson is the General Counsel of Kriya Therapeutics. Previously, Ms. Johnson was General Counsel at Rakuten Medical, and Vice President and Head of Legal Affairs and Corporate Compliance at Gritstone Oncology. Ms. Johnson has also held roles at BioMarin Pharmaceutical as well as at Reed Smith LLP, a leading global law firm. Ms. Johnson brings extensive legal life sciences industry experience in both private and public companies, in areas as varied as IPOs, complex transactions, corporate governance, litigation, compliance, and ethics.

Ms. Johnson received her JD from the University of San Francisco School of Law and her undergraduate degree in English Literature from Vanderbilt University.

<   PreviousNext   >

Brian Furmanski, PhD

Vice President, Regulatory Affairs

Brian Furmanski, PhD

Vice President, Regulatory Affairs

Brian Furmanski is the Vice President of Regulatory Affairs at Kriya Therapeutics. Previously, Dr. Furmanski was the Senior Director of Clinical Pharmacology and Regulatory Affairs at Nuventra Pharma Sciences. Prior to Nuventra, Dr. Furmanski was a Senior Clinical Pharmacology Reviewer at the FDA where he reviewed and provided regulatory and scientific advice on hundreds of IND, NDA, and BLA submissions. Before his time at the FDA, Dr. Furmanski was an investigator in the muscle metabolism and repair group at GlaxoSmithKline. He started his career at Siga Technologies where he contributed to the development of novel antiviral therapies.

Dr. Furmanski received his PhD in biochemistry from the University of South Carolina and completed his postdoctoral fellowship at St. Jude Children’s Research Hospital. He received his undergraduate degrees in Economics and Engineering from the University of South Carolina.

<   PreviousNext   >

Image of Jason Mallory, PhD

Jason Mallory, PhD

Vice President of Clinical Development

Image of Jason Mallory, PhD

Jason Mallory, PhD

Vice President, Clinical Development

Jason Mallory is the Vice President of Clinical Development at Kriya Therapeutics. Previously, Dr. Mallory was a Clinical Development Leader at Spark Therapeutics, where he focused on liver-targeted AAV gene therapy programs including in Pompe disease, Hemophilia A, and early-stage programs. Prior to Spark, Jason led clinical development activities spanning all phases of drug development for gene therapy programs at GlaxoSmithKline (including on Libmeldy™, a gene therapy for metachromatic leukodystrophy recently approved by the EMA) and Adverum Biotechnologies. Prior to his work in the field of gene therapy, Dr. Mallory spent approximately ten years in clinical development for more prevalent diseases, including for the development and successful global licensure of albiglutide for patients with type 2 diabetes mellitus.

Dr. Mallory received his PhD in Molecular Biology and Genetics and completed his postdoctoral work at the University of Southwestern Medical Center and the Institute of Metabolic Disease at Baylor University Medical Center. Dr. Mallory received his master’s degree in Molecular Biology and Genetics from Baylor University Medical Center, and his undergraduate degree in Biology at Midwestern State University, Wichita Falls.

<   PreviousNext   >

Ashlyn Bassiri, PhD

Vice President, Immunology

Ashlyn Bassiri, PhD

Vice President, Immunology

Ashlyn Bassiri is the Vice President of Immunology at Kriya Therapeutics. Previously, Dr. Bassiri was the Head of Translational Safety at CSL Behring. Prior to this, she was the Pharmacovigilance Leader for all liver-targeted programs at Spark Therapeutics, and supported the US and European filings for LUXTURNA®. She spent ten years in R&D at GlaxoSmithKline where she focused on immune toxicities in both the nonclinical and clinical safety groups, eventually chairing the Immune Safety panel.

Dr. Bassiri received her PhD in Immunology from the University of Pennsylvania School of Medicine, and her master’s and undergraduate degrees in Biomedical Sciences and Immunology from Ohio University.

<   PreviousNext   >

Zhu Pirot, PhD

Vice President, Translational Sciences

Zhu Pirot, PhD

Vice President, Translational Sciences

Zhu Pirot is the Vice President of Translational Sciences at Kriya Therapeutics. Previously, Dr. Pirot was the head of analytical method development, CMC lead at Sangamo Therapeutics where she built and led the analytical function for AAV-mediated gene therapy, gene editing, and cell therapy programs. She has more than 20 years of experience in drug development and has held positions of increasing responsibility at Chiron, Avigen, and Geron.

Dr. Pirot received her Medical Degree from Inner Mongolia Medical College. She completed her master’s degree in Cytogenetics from Beijing Cancer Institute and her PhD in Cellular and Molecular Biology from the University of Turin.

<   PreviousNext   >

Michele Stone, PhD

Vice President, Translational Development

Michele Stone, PhD

Vice President, Translational Development

Michele Stone is the Vice President of Translational Development at Kriya Therapeutics. Previously, Dr. Stone was the Vice President of Early Development and Head of Nonclinical and Bioanalytical at Axovant Gene Therapies (now Sio Gene Therapies). Prior to this, Dr. Stone was Executive Director of Vaccine Development and Bioanalytical at Liquidia Technologies. Dr. Stone was also the Director of R&D at Aeras where she was responsible for developing and leading partnerships to advance multiple vaccine platforms (viral vector, protein, and nucleic acid) into and through clinical development. She was previously a Senior Scientist at Canon US Life Sciences where she contributed to the development of diagnostics aimed at personalized medicine.

Dr. Stone received her PhD in Biochemistry and Molecular Biology from the University of Maryland, where she also completed her postdoctoral fellowship in Physiology and Neuroscience. She received her undergraduate degree in Chemistry from Lynchburg College.

<   PreviousNext   >

Image of Lily Nguyen

Lily Nguyen

Vice President, Project Management

Image of Lily Nguyen

Lily Nguyen

Vice President, Project Management

Lily Nguyen is the Vice President of Project Management at Kriya Therapeutics. Previously, Ms. Nguyen was Director of Program and Alliance Management at SpringWorks Therapeutics, a company focused on advancing therapies in rare disease and oncology, where she supported development teams to plan and execute on global clinical studies and managed development programs with alliance partners. Prior to SpringWorks, Ms. Nguyen was Senior Director of Program Management at Roivant Sciences where she led planning and organization of drug development projects. She has over 15 years of drug development experience and has held project management roles of increasing responsibility at Aerie, Cempra, and Synthon Pharmaceuticals.

Ms. Nguyen received her MBA from the University of North Carolina at Chapel Hill and her undergraduate degree in Chemical Engineering from North Carolina State University.

<   PreviousNext   >

Joseph Rabinowitz, PhD

Vice President, Process Sciences

Joseph Rabinowitz, PhD

Vice President, Process Sciences

Joseph Rabinowitz is the Vice President of Process Sciences at Kriya Therapeutics. He has more than 20 years of experience in the development of AAV vectors. Previously, Dr. Rabinowitz was the Senior Director of Capsid Development at Pfizer in the Rare Disease Research Unit where he led a team generating AAV viral libraries. Prior to working at Pfizer, he was a member of the faculty at Temple University and Thomas Jefferson University.

Dr. Rabinowitz received his PhD in genetics from Case Western Reserve University and completed his postdoctoral fellowship in Gene Therapy at the University of North Carolina at Chapel Hill. He received his undergraduate degree in Microbiology from the University of Arizona, Tucson.

<   PreviousNext   >

Mitch Lower

Vice President, Technical Operations

Mitch Lower

Vice President, Technical Operations

Mitch Lower is the Vice President of Technical Operations at Kriya Therapeutics. Previously, Mr. Lower was the Vice President of Global Engineering and Facilities at AveXis, a Novartis company, where he was responsible for the implementation and management of the company’s manufacturing capabilities and support of its engineering and facilities global network. Prior to AveXis, Mr. Lower held positions of increasing responsibility at Biogen for more than 20 years in roles across technical operations, engineering and facilities, manufacturing, supply chain, and network strategy.

Mr. Lower received his MBA from Duke University and his undergraduate degree in Mechanical Engineering from North Carolina State University.

<   PreviousNext   >

Stephen Soltys

Vice President, Process Development

Stephen Soltys

Vice President, Process Development

Stephen Soltys is the Vice President of Process Development at Kriya Therapeutics. Previously, Mr. Soltys was Director of the Manufacturing Science and Technology (MSAT) labs at AveXis, a Novartis company, where he led a team of upstream, downstream, and analytical scientists. Prior to Avexis, Stephen designed the manufacturing processes for multiple gene therapy companies, including Precision Biosciences and Bamboo Therapeutics (a Pfizer, Inc. subsidiary), and was a process development scientist at the University of North Carolina Gene Therapy Center.

Mr. Soltys received his master’s degree in Molecular Biology from Thomas Jefferson University and his undergraduate degree in Biology from Marietta College.

<   PreviousNext   >

Image of Harold Alterson

Harold Alterson

Vice President, Quality

Image of Harold Alterson

Harold Alterson

Vice President, Quality

Harold Alterson is the Vice President of Quality at Kriya Therapeutics. Prior to joining Kriya, Mr. Alterson was most recently Senior Director of Quality Control and CMC Lead at bluebird bio. He was part of the team involved in the construction and startup of bluebird bio’s first internal manufacturing facility. While at bluebird bio, Mr. Alterson was responsible for building out the Quality Control team at the site to support facility qualification and routine operations. Prior to bluebird, he held positions of increasing responsibility in Quality Assurance at Biogen with roles overseeing Quality Engineering, Quality Systems, and Quality Operations. He spent the early part of his career in research and development focused on alphavirus vectors for vaccine use at AlphaVax.

Mr. Alterson received his undergraduate degree in microbiology from Montana State University.

<   PreviousNext   >

Erik Hughes, PhD

Vice President, Applied Science and Technology

Erik Hughes, PhD

Vice President, Applied Science and Technology

Erik Hughes is the Vice President of Applied Science and Technology at Kriya Therapeutics. Previously, Dr. Hughes held roles at Biogen including as Director of Global Process Sciences and Director of North American Manufacturing Sciences. He was responsible for partner relationships, development of second-generation processes, technology transfer, process scale-up, GMP cell banking, process compliance, and lifecycle management across a portfolio of commercial and clinical products. Prior to Biogen, Dr. Hughes worked at Wyeth Research where he was involved in upstream process development for Prevnar13® and a meningococcal group B vaccine.

Dr. Hughes received his PhD in Chemical Engineering and his undergraduate degrees in Chemical Engineering and Economics from Rice University.

<   PreviousNext   >

Bruce Schnepp, PhD

Senior Director, Technology Development

Bruce Schnepp, PhD

Senior Director, Technology Development

Bruce Schnepp is the Senior Director of Technology Development at Kriya Therapeutics. Previously, Dr. Schnepp was a Research Scientist at Limelight Bio where he led a team of scientists developing both AAV-mediated and non-viral therapeutics for genetic diseases. Prior to Limelight Bio, Bruce was a Scientist at The Children’s Hospital of Philadelphia where he was involved in the preclinical design and development of the first-in-human study that used a recombinant AAV vector to deliver a gene for a monoclonal antibody to block HIV infection. He has more than 20 years of experience in rAAV gene transfer, as well as vector biodistribution, safety, and genome persistence.

Dr. Schnepp received his PhD in Molecular Genetics from The Ohio State University and completed his postdoctoral work at Nationwide Children’s Hospital. He received his undergraduate degree in Biology from Purdue University.

<   PreviousNext   >

Amy Chen

Sr. Director, Corporate Controller

Amy Chen

Sr. Director, Corporate Controller

Amy Chen is the Corporate Controller at Kriya Therapeutics. Prior to joining Kriya, Ms. Chen worked at Jazz Pharmaceuticals as the Director of Accounting, supporting all aspects of the company’s US accounting operations and related SOX compliance. Before Jazz, she was the Assistant Controller at Natera, where she played a key role in the company’s accounting readiness for its initial S-1 filing. Ms. Chen also worked at JDSU, a high tech company, with roles in both technical accounting and BU finance. Ms. Chen started her career in public accounting with Deloitte and subsequently Ernst & Young, serving both public and private audit clients across various industries. She is a Certified Public Accountant actively licensed in the state of California.

Ms. Chen received her master’s of science in Economics from Southern Illinois University at Carbondale and her master’s of Accountancy from the University of Georgia. She received her undergraduate degree in Economics from Zhongnan University of Economics of Law in China.

<   PreviousNext   >

Jed Leviner

Sr. Director & Head of Information and Operational Technology

Jed Leviner

Sr. Director & Head of Information and Operational Technology

Jed Leviner is the Senior Director and Head of Information and Operational Technology at Kriya Therapeutics. Previously, Mr. Leviner was the Executive Director of Information Technology at Liquidia Technologies, where he developed and led the execution of the technology strategy to transition from R&D and clinical manufacturing to commercial manufacturing. Mr. Leviner was also the Director of Information Technology and Automation for Medicago, where he scaled the technology strategy, infrastructure, and operations in the build-out of a DARPA funded manufacturing facility in North Carolina and the conceptual design of a commercial-scale facility in Quebec. Mr. Leviner began his career with Campbell Soup Company and held various roles of increasing responsibility in manufacturing automation and information technology before transitioning to the Life Sciences industry.

Mr. Leviner received his undergraduate degree in Business Administration from Appalachian State University.

<   PreviousNext   >

Veronica Wong

Sr. Director, Corporate Legal & Compliance

Veronica Wong

Sr. Director, Corporate Legal & Compliance

Veronica Wong is the Senior Director of Corporate Legal & Compliance at Kriya Therapeutics. Previously, Ms. Wong was Director of Legal & Compliance at Gritstone Oncology, Inc., where she was responsible for leading contracting and compliance efforts, implementation of legal and compliance systems, and management of financing and corporate activities. Ms. Wong brings over a decade of legal operations and corporate compliance experience in the life sciences industry, covering all phases of research and development.

Ms. Wong received her undergraduate degree from the University of California, Davis.

<   PreviousNext   >

Jiewu Liu, PhD

Director, Bioanalytical Science

Jiewu Liu, PhD

Director, Bioanalytical Science

Jiewu Liu is the Director of Bioanalytical Science at Kriya Therapeutics. He has over 10 years of combined experience in bioanalytical assay development and validation. Previously, Dr. Liu was an associate director at Cambridge Biomedical (acquired by BioAgilytix Labs) where he built and led a team to provide bioanalytical support for drug development under GxPs. Before that, Dr. Liu served as bioanalysis manager at Enzyvant and its parent company Roivant Sciences where he was responsible for bioanalytical method development and validation. He held positions of increasing responsibility at Vascular Pharmaceuticals, Argos Therapeutics, and BioAgilytix.

Dr. Liu received his PhD in Biochemistry and Molecular Biology from the Shanghai Institute of Biochemistry and Cell Biology, and completed his postdoctoral fellowship at St. Jude Children’s Hospital and Weill Medical College of Cornell University. Dr. Liu received his master’s degree in Biochemistry from Nankai University.

<   PreviousNext   >

Rich Guerra

Director, Technical Operations

Rich Guerra

Director, Technical Operations

Rich Guerra is the Director of Technical Operations at Kriya Therapeutics. Previously, Mr. Guerra was a Senior Project Manager at Clark, Richardson, and Biskup Consulting Engineers where he was responsible for managing the delivery of capital projects from concept through detailed design. Prior to CRB, Mr. Guerra held leadership roles within Engineering, Manufacturing, and Manufacturing Science and Technology at Biogen, where he was responsible for the execution of capital projects, leading startup of new manufacturing facilities, supporting technology transfer of new products, and managing cGMP clinical and commercial manufacturing operations. Prior to Biogen, Mr. Guerra has held roles of increasing scope and responsibility as a senior engineer at Amgen.

Mr. Guerra received his undergraduate degree in Chemical Engineering from the University of Illinois at Urbana-Champaign.

<   PreviousNext   >

Mark Chen

Director, Manufacturing Strategy & Program Management

Mark Chen

Director, Manufacturing Strategy & Program Management

Mark Chen is the Director of Manufacturing Strategy and Program Management at Kriya Therapeutics. Previously, Mr. Chen was the Associate Director, Strategic Partnerships at Biogen where he was responsible for the strategic relationship management and day-to-day oversight of Biogen’s insourcing manufacturing commitments. Prior to this, he held roles of increasing responsibility within Biogen across the Manufacturing, Technical Development, and Manufacturing Sciences organizations.

Mr. Chen received his MBA from Duke University and his undergraduate degree in Biological Sciences from North Carolina State University.

<   PreviousNext   >

Justin Reehl

Director, Engineering and Facilities

Justin Reehl

Director, Engineering and Facilities

Justin Reehl is the Director of Engineering and Facilities at Kriya Therapeutics. Previously, Mr. Reehl was Senior Engineer, Global Engineering at Biogen. Mr. Reehl brings over 15 years of end-to-end engineering, project, and facility design experience relevant to the gene therapy field, and has expertise in traditional biologics, single use manufacturing, and oligonucleotide processes.

Mr. Reehl is a Registered Professional Engineer in North Carolina and received his undergraduate degree in Chemical Engineering from Lehigh University.

<   PreviousNext   >

Jennifer Coggburn

Director, Human Resources

Jennifer Coggburn

Director, Human Resources

Jennifer Coggburn is the Director of Human Resources at Kriya Therapeutics. Previously, Ms. Coggburn was the Senior Benefits Program Manager at the IBM Corporation where she worked for over 10 years. Prior to IBM, she was a Senior Human Resource Partner and Compensation manager at Citigroup.

Ms. Coggburn received her master’s degree in Human Resources at the University of South Carolina and her undergraduate degree in Management at the University of Nebraska-Lincoln.

<   PreviousNext   >

Image of Peter McElerney

Peter McElerney

Director, Finance

Image of Peter McElerney

Peter McElerney

Director, Finance

Peter McElerney is Director of Finance at Kriya Therapeutics. Previously, Mr. McElerney was Finance Director Global SG&A at Patheon (part of Thermo Fisher Scientific) where he was responsible for planning, managing, and analyzing investments in Global SG&A. Prior to his time at Patheon, he was Controller and Finance Manager at BD Technologies, a medical device company.

Mr. McElerney received his MBA from Iona College and his undergraduate degree in Economics from the State University of New York at Albany.

<   PreviousNext   >

Weiran Shen, PhD

Associate Director, Vector Design and Innovation

Weiran Shen, PhD

Associate Director, Vector Design and Innovation

Weiran Shen is the Associate Director of Vector Design and Innovation at Kriya Therapeutics. Previously, Dr. Shen was a lead scientist at Sangamo Therapeutics, where he led the efforts to design novel AAV vectors to treat CNS diseases. Prior to Sangamo, Dr. Shen led a group at the discovery lab in the Gene Therapy Program at the University of Pennsylvania where he was involved in designing gene therapy vectors and developing and improving vector production systems.

Dr. Shen received his PhD in Microbiology from the University of Kansas Medical Center and completed his postdoctoral fellowship at the University of Pennsylvania. He received his master’s degree in Neuroscience at Second Military Medical University and his undergraduate degree in Biology from Southwest University in China.

<   PreviousNext   >

Yunchao Gai, PhD

Associate Director, Analytical Sciences

Yunchao Gai, PhD

Associate Director, Analytical Sciences

Yunchao Gai is the Associate Director of Analytical Sciences at Kriya Therapeutics. Previously, Dr. Gai led teams in the fields of diagnostics and therapeutics at Sangamo Therapeutics and Koniku Inc. He has more than 15 years of experience in the fields of molecular and cellular biology.

Dr. Gai received his PhD in Innate Immunity from the Chinese Academy of Sciences, and completed his postdoctoral training in Immunology at the University of Missouri and in Neuroscience at the Scripps Research Institute. Dr. Gai received his undergraduate degree in Biotechnology from the Hefei University of Technology.

<   PreviousNext   >

Shuailiang Lin, PhD

Associate Director, Translational Sciences

Shuailiang Lin, PhD

Associate Director, Translational Sciences

Shuailiang Lin is the Associate Director of Translational Sciences at Kriya Therapeutics. Previously, Dr. Lin was the Director of Genome Editing at Ligandal Inc, where he built and led a team focused on gene editing, gene delivery, and TCR engineering of T cells. Dr. Lin was also part of the early team involved in the development of the CRISPR/Cas9 genome engineering system in Feng Zhang’s lab at The Broad Institute. He has more than 10 years of experience in genome engineering and gene delivery.

Dr. Lin received his PhD from Tsinghua University and completed his postdoctoral fellowship at the University of California, San Francisco. He received his undergraduate degree in Biological Sciences from the China Agricultural University.

<   PreviousNext   >

Fernie Mitchelson, PhD

Associate Director, Process Development

Fernie Mitchelson, PhD

Associate Director, Process Development

Fernie Mitchelson is the Associate Director of Process Development at Kriya Therapeutics. Previously, Dr. Mitchelson was Senior Engineer of Process Sciences in the Global Manufacturing Sciences department at Biogen, where she managed cell culture tech transfers of biologics from external partners and supported commercial biologics manufacturing.

Dr. Mitchelson received her PhD in Chemical Engineering from the Georgia Institute of Technology and her undergraduate degree in Chemical Engineering from the University of Virginia.

<   PreviousNext   >

Dylan Clark

Associate Director, Operations Technology

Dylan Clark

Associate Director, Operations Technology

Dylan Clark is the Associate Director of Operations Technology at Kriya Therapeutics. Previously, Mr. Clark was the Senior Manager of Quality Control Systems at bluebird bio where he provided leadership in the implementation, validation, and management of computer systems and instruments and also led data integrity initiatives. Prior to bluebird bio, Mr. Clark held positions of increasing responsibility over twelve years at the consulting firm Sequence, Inc., most recently overseeing the Software and Data Management business unit.

Mr. Clark received his master’s degree in Information Systems from DePaul University and his undergraduate degree in Biology from Butler University.

<   PreviousNext   >

Beth Marbois, PhD

Principal Scientist, Process Analytics Group Leader

Beth Marbois, PhD

Principal Scientist, Process Analytics Group Leader

Beth Marbois is Principal Scientist in the Process Analytics Group at Kriya Therapeutics. Dr. Marbois has extensive experience working at the bench and leading teams to develop, qualify, and execute release methods to measure AAV, mRNA, proteins, and small molecules for quality and safety decision making. Dr. Marbois previously held positions at Precision BioSciences, GlaxoSmithKline, Novartis, bioMerieux, and Atairgin Technologies.

Dr. Marbois received her PhD in Biological Chemistry from the University of California, Los Angeles Intellectual and Development Disabilities Research Center, where she also completed her postdoctoral fellowship and received her master’s degree in Science and Public Health in Nutritional Sciences.

<   PreviousNext   >

Michael Lovci, PhD

Michael Lovci, PhD

Senior Bioinformatics Scientist

Michael Lovci, PhD

Michael Lovci, PhD

Senior Bioinformatics Scientist

Michael Lovci is the Senior Bioinformatics Scientist at Kriya Therapeutics. Previously, Dr. Lovci worked on cross-disciplinary teams developing techniques for nucleic acid assays at NuGEN, built automated diagnostic platforms in oncology at Driver, and designed microbial genomes for biosynthesis of high-value chemicals at Intrexon. He has extensive experience in the discovery of RNA regulatory controls and in leveraging computation for biological engineering.

Dr. Lovci received his PhD in Biomedical Sciences and his undergraduate degree in Biology from the University of California, San Diego.

<   PreviousNext   >

Tyler Goodwin

Tyler Goodwin, PhD

Sr. Scientist, Drug Product

Tyler Goodwin

Tyler Goodwin, PhD

Sr. Scientist, Drug Product

Tyler Goodwin is a Senior Scientist and Group Lead of Drug Product Process Development at Kriya. Previously, Dr. Goodwin was CMC Lead and Scientist in the Process Science team at Precision BioSciences, where he led a team of scientists and engineers in developing viral and non-viral gene delivery systems from pre-clinical to clinical stage studies for gene and cell therapies.

Dr. Goodwin received his PhD in Pharmacoengineering and Molecular Pharmaceutics from the University of North Carolina Chapel Hill. He received his master’s and undergraduate degrees in Chemistry from the University of North Carolina Wilmington.

<   PreviousNext   >

Dawn Fellner

Senior Scientist

Dawn Fellner

Senior Scientist

Dawn Fellner is a Senior Scientist on the Translational Development team at Kriya Therapeutics. Previously, Ms. Fellner worked in nonclinical operations roles at Intertek and Roivant Sciences. She also previously worked as a technician and project manager at Charles River Laboratories.

Ms. Fellner received her undergraduate degree in Biology from Kent State University.

<   PreviousNext   >

Dana McKinney

Senior Manager, Quality Systems

Dana McKinney

Senior Manager, Quality Systems

Dana McKinney is Senior Manager of Quality Systems at Kriya Therapeutics. Previously, Ms. McKinney was Manager of Quality Control, Raw Materials at bluebird bio where she was responsible for creating a raw material program for the company’s first internal manufacturing site. Prior to bluebird bio, Ms. McKinney was part of a team involved in the construction of the new facility for the Diabetes Active Pharmaceutical Ingredients – US Project at Novo Nordisk. Ms. McKinney has also held various roles in Quality at Biogen and Catalent Pharma Solutions.

Ms. McKinney received her master’s degree in Public Health from Emory University and her undergraduate degree in Biological Sciences from North Carolina State University.

<   PreviousNext   >

Emilia Bora

Sr. Manager, Vector Core

Emilia Bora

Sr. Manager, Vector Core

Emilia Bora is Senior Manager, Vector Core in Translational Sciences at Kriya Therapeutics. Ms. Bora has worked in the biotech industry since 2006 for Fortune 100 companies as well as startups from early stage through IPO. She has broad expertise in Research and Development, Quality Control, Process Development, Clinical Testing and a strong focus in Analytical Development.

Ms. Bora received her master’s degree in Biology from Tufts University and her undergraduate degree in Biology from the University of Bucharest.

<   PreviousNext   >

Brandy Bateman

Manager, Quality Assurance

Brandy Bateman

Manager, Quality Assurance

Brandy Bateman is Quality Assurance Manager at Kriya Therapeutics. Previously, Ms. Bateman was the Quality Control Lead for the Sample Control department at bluebird bio. She was a part of the facility’s startup team, leading the development of processes and helping to build the initial team. Prior to bluebird bio, Ms. Bateman was a part of the Quality Assurance team at Biogen, holding positions in Quality Engineering and Quality Operations. She spent her early career at Biogen in Technical Development.

Ms. Bateman received her master’s degree in regulatory science from Johns Hopkins University and her undergraduate degree in Biological Sciences from North Carolina State University.

<   PreviousNext   >

Rob Ballard

Manager, Manufacturing Operations

Rob Ballard

Manager, Manufacturing Operations

Rob Ballard is the Manager of Manufacturing Operations at Kriya Therapeutics. Previously, Mr. Ballard was Engineering Supervisor at Biogen. He has extensive experience with manufacturing processes related to biologics and gene therapy.

Mr. Ballard received his undergraduate degree in Chemical Engineering from North Carolina State University.

<   PreviousNext   >

Kristopher Britt

Manager, Supply Chain

Kristopher Britt

Manager, Supply Chain

Kris Britt is Supply Chain Manager at Kriya Therapeutics. Previously, Mr. Britt was the Purchasing Supervisor at AveXis, a Novartis company where he was responsible for direct and indirect purchasing as well as all materials management activities involved in the implementation of the company’s North Carolina manufacturing facility. Prior to AveXis, Mr. Britt worked for Organon Teknika (a part of Merck & Co., Inc.), Merck & Co, Inc., and Biogen, holding positions of increasing responsibility within supply chain management.

Mr. Britt received his undergraduate degree in Business Management from East Carolina University.

<   PreviousNext   >

Eva Tung

Manager, Accounting

Eva Tung

Manager, Accounting

Eva Tung is an Accounting Manager at Kriya Therapeutics. Ms. Tung has worked in the accounting field for 15 years in both private and publicly held companies. Most recently, Ms. Tung served as Senior Accountant at Tile Inc where she was responsible for streamlining various accounting processes and handling month end close procedures. Prior to Tile, Ms. Tung worked for pharmaceutical companies, including Natera and Coherus. At Natera, Ms. Tung led a team of four people and oversaw the accounting areas of general ledger and accounts payable.

Ms. Tung received her undergraduate degree in Accounting from San Jose State University, California.

<   PreviousNext   >

Allison Lewis

Scientist

Allison Lewis

Scientist

Allison Lewis is a Scientist at Kriya Therapeutics. Previously, Ms. Lewis was an Associate Scientist at Pfizer where she worked in AAV production. She subsequently transitioned to the capsid development team within the Rare Disease Research Unit at Pfizer.

Ms. Lewis received her undergraduate degree in Pharmaceutical Sciences from North Carolina Central University.

<   PreviousNext   >

Michael Walker

Scientist

Michael Walker

Scientist

Michael Walker is a Scientist in the process sciences lab at Kriya Therapeutics. Previously, Mr. Walker was a Research Assistant at Precision BioSciences. He has experience in molecular cloning, plasmid purification, and GLP vector production. Mr. Walker also served as a Combat Engineer in the United States Army.

Mr. Walker received his undergraduate degree in Ecology and Evolutionary Biology from East Carolina University.

<   PreviousNext   >

Megan Walz

Engineer, Bioprocess

Megan Walz

Engineer, Bioprocess

Megan Walz is a Process Engineer at Kriya Therapeutics. Previously, Ms. Walz was a Manufacturing Associate and Engineer at bluebird bio where she was part of the team involved in the construction and start-up of the company’s first internal manufacturing facility and preparation of the facility for GMP manufacturing. Prior to bluebird bio, Ms. Walz was a Research Associate in a microbial fermentation process development group at Novozymes and spent time as a Research Assistant at bioMASON.

Ms. Walz received her master’s degree in Biosystems Engineering from the University of Kentucky and her undergraduate degree in Biology from North Carolina State University.

<   PreviousNext   >

Amit Weiss

Amit Weiss

Sr. Research Associate & Lab Manager

Amit Weiss

Amit Weiss

Sr. Research Associate & Lab Manager

Amit is a Senior Research Associate and Lab Manager at Kriya Therapeutics. Previously, Amit worked as a Research Associate with Neucyte’s manufacturing team to produce materials for Neucyte’s induced pluripotent stem cell technology program. Prior to Neucyte, he was a Lab Technician at Koniku, responsible for executing and optimizing cell-based assays for compound screening. Prior to Koniku, he gained experience in a wide range of academic labs focusing on the cell biology of HIV, early mouse development, and cell cycle in yeast, among other areas.

Mr. Weiss received his undergraduate degree in Molecular, Cell and Developmental Biology from the University of California, Santa Cruz.

<   PreviousNext   >

Ilya Slabodkin

Senior Research Associate

Ilya Slabodkin

Senior Research Associate

Ilya Slabodkin is a Senior Research Associate at Kriya Therapeutics. Prior to joining Kriya, Mr. Slabodkin was a Research Associate at Just, Inc. where he was responsible for cell line development and adaptation. Prior to Just, Mr. Slabodkin was a Research Associate at BioMarin Pharmaceutical, where he worked in viral vector process development. Earlier in his career, Mr. Slabodkin was a Research Associate in Discovery Biology at Cytokinetics.

Mr. Slabodkin received his undergraduate degree in Biological Science and Neuroscience Physiology Behavior at the University of California, Davis.

<   PreviousNext   >

Dorothee Grall

Office Manager & Executive Administrative Assistant

Dorothee Grall

Office Manager & Executive Administrative Assistant

Dorothee Grall is an Office Manager and Executive Administrator at Kriya Therapeutics. Previously, Dorothee worked at Intel Corporation as a Project Manager. In that role, she was responsible for customer experiences in the Executive Briefing Center. She was also Lead Administrator in the Sales and Marketing Organization and co-created the Field Sales Business Continuity Program for remote field employees in the US and Canada.

Ms. Grall received her undergraduate degree in Spanish, Foreign Languages and International Marketing from San Jose State University.

<   PreviousNext   >

Diana Fortner

Office Manager & Executive Administrator

Diana Fortner

Office Manager & Executive Administrator

Diana Fortner is an Office Manager and Executive Administrator at Kriya Therapeutics. Previously, Ms. Fortner was Executive Assistant at Enzyvant Therapeutics, a company focused on breakthrough biotechnologies and transformative therapies for people with suffering from rare diseases. Prior to this, she worked at Roivant Sciences as office administrator and senior administrative assistant to the Vice Presidents of CMC, Regulatory, and Clinical Development. She also has prior experience with the United States Department of Defense.

<   Previous